Abstract
A trial update confirms improved survival for prophylactic elective nodal irradiation and addition of erlotinib to definitive chemoradiotherapy in oesophageal squamous cell carcinoma (ESCC). High tumour EGFR protein expression shows promise to identify those who will benefit from erlotinib. This represents therapeutic progress, and has wider relevance for precision medicine strategies in ESCC.
| Original language | English |
|---|---|
| Pages (from-to) | 1585-1587 |
| Number of pages | 3 |
| Journal | British Journal of Cancer |
| Volume | 123 |
| Issue number | 11 |
| Early online date | 22 Sept 2020 |
| DOIs | |
| Publication status | Published - 24 Nov 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Oesophageal cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Combining precision medicine and prophylaxis in oesophageal squamous cell carcinoma'. Together they form a unique fingerprint.Projects
- 2 Finished
-
Identifying and Validating Predictive Biomarkers in Advanced Oesophagael Adenocarcinoma - A Springboard to REAListic Medicine (BE-REAL)
Baxter, M. (Investigator)
1/10/20 → 29/02/24
Project: Research
-
Understanding Resistance to Targeted Therapies in Oesophageal Squamous Cell Carcinoma as a Foundation to Developing New Precision Medicine Approaches
Petty, R. (Investigator)
1/03/20 → 31/03/23
Project: Research
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver